Lastly, as cancer treatment paradigms shift toward combination therapies, future investigations should explore the potential of PD-1/PD-L1 inhibitors in conjunction with other treatments to enhance therapeutic outcomes for recurrent OC patients. This evidence concerns the gene PDCD1 and cancer.